EUVIMEDEUVIMED entdecken
Open Access

Glioblastoma Multiforme Oncogenomics and Signaling Pathways

Okezie O Kanu, Betsy Hughes, Chunhui Di, Ningjing Lin, Jinrong Fu, Darell D Bigner, Hai Yan, Cory Adamson

Clinical medicine. Oncology · 2009

DOI: 10.4137/cmo.s1008 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical medicine. Oncology, 2009. Verfasst von Okezie O Kanu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Lagos University Teaching Hospital, Lagos, Nigeria. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 136 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In the adult population, glioblastoma multiforme is one of the most common primary brain tumors encountered. Unfortunately, this highly malignant tumor represents over 50% of all types of primary central nervous system gliomas. The vast majority of GBMs develops quite rapidly without clinical, radiological, or morphologic evidence of a less malignant precursor lesion (primary or de novo GBMs), as compared to secondary GBMs that develop slowly by progression from diffuse low-grade astrocytomas. These GBM subtypes must be kept in mind because they may constitute distinct disease entities. Even though they look histologically quite similar, they likely involve different genetic alterations and signaling pathways. Decades of surgical therapy, radiotherapy, and chemotherapy have failed to drastically change survival. Clearly, we do not fully understand this tumor; however, the exciting genetic revolution in glioma research over the past decade is providing a promising outlook for exploring this tumor at the genetic level. Science has begun to elucidate the numerous genetic alterations and critical signaling pathways, and it has opened new exciting areas of research such as glioma stem cell biology and neoangiogenesis. This work has already begun to improve our understanding of GBM cell proliferation, migration, and invasion. Indeed, exciting novel targeted therapies are making their way to clinical trials based on this increased knowledge. This review provides the current understanding of GBM oncogenomics, signaling pathways, and glioma stem cell biology and discusses the potential new therapeutic targets on the horizon.

Autor:innen und Institutionen

  • Lagos University Teaching Hospital, Lagos, Nigeria.

Förderung

  • NCI NIH HHS

Zitieren

APA

Kanu, O. O., Hughes, B., Di, C., Lin, N., Fu, J., Bigner, D. D., Yan, H., & Adamson, C. (2009). Glioblastoma Multiforme Oncogenomics and Signaling Pathways. Clinical medicine. Oncology. https://doi.org/10.4137/cmo.s1008

Vancouver

Kanu OO, Hughes B, Di C, Lin N, Fu J, Bigner DD, et al. Glioblastoma Multiforme Oncogenomics and Signaling Pathways. Clinical medicine. Oncology. 2009. doi:10.4137/cmo.s1008

BibTeX
@article{Kanu2009,
  author = {Kanu, Okezie O and Hughes, Betsy and Di, Chunhui and Lin, Ningjing and Fu, Jinrong and Bigner, Darell D and Yan, Hai and Adamson, Cory},
  title = {Glioblastoma Multiforme Oncogenomics and Signaling Pathways},
  journal = {Clinical medicine. Oncology},
  year = {2009},
  doi = {10.4137/cmo.s1008}
}
Kostenlos starten →